The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Open accessAbstract
BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS: In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching individually appropriate glycemic targets in all patients. To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The primary cardiovascular outcome was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. RESULTS: During a median follow-up of 3.0 years, there was a small difference in glycated hemoglobin levels (least-squares mean difference for sitagliptin vs. placebo, -0.29 percentage points; 95% confidence interval [CI], -0.32 to -0.27). Overall, the primary outcome occurred in 839 patients in the sitagliptin group (11.4%; 4.06 per 100 person-years) and 851 patients in the placebo group (11.6%; 4.17 per 100 person-years). Sitagliptin was noninferior to placebo for the primary composite cardiovascular outcome (hazard ratio, 0.98; 95% CI, 0.88 to 1.09; P<0.001). Rates of hospitalization for heart failure did not differ between the two groups (hazard ratio, 1.00; 95% CI, 0.83 to 1.20; P=0.98). There were no significant between-group differences in rates of acute pancreatitis (P=0.07) or pancreatic cancer (P=0.32). CONCLUSIONS: Among patients with type 2 diabetes and established cardiovascular disease, adding sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular events, hospitalization for heart failure, or other adverse events. (Funded by Merck Sharp & Dohme; TECOS ClinicalTrials.gov number, NCT00790205.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There are a number of other trials regarding cardiovascular outcomes in high-risk cohorts of patients with type 2 diabetes in which similar magnitude effects on glycemic control have been shown but without significant benefits with respect to rates of cardiovascular events or death.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“have shown that DPP4i exhibit cardiovascular neutrality in T2DM patients.”
From The effect of GLP ‐1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta‐analysis (2025) · cites this paper as [136]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence that glucose lowering reduces the rates of cardiovascular events and death has not been convincingly shown, 4-6”
From Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (2015) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Across the trials of this drug class, there appears to be no interaction by age-group (110-112).”
From 13. Older Adults: Standards of Care in Diabetes—2024 (2024) · cites this paper as [111]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, three other cardiovascular outcomes trials-Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) (293), Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) (294), and the Cardiovascular and Renal Microvascular Outcome Study With Linagliptin (CARMELINA) (295)-did not find a significant increase in risk of heart failure hospitalization with D”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [294]
The cited source says what the claim attributes to it.
In the citing paper
“However, three other cardiovascular outcomes trials—Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) (312), Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) (313), and the Cardiovascular and Renal Microvascular Outcome Study With Linagliptin (CARMELINA) (314)—did not find a significant increase in risk of heart failure hospitalization with D”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [313]
The cited source says what the claim attributes to it.
In the citing paper
“The comparator, sitagliptin, served as a placebo proxy regarding the outcome of interest as it showed no effect on heart failure events in a major randomized clinical trial and previously successfully served as a placebo proxy in claims data analyses.15,18,19”
From Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction (2025) · cites this paper as [19]
In the citing paper
“The observed annualized primary endpoint event rate for placebo patients in REDUCE-IT was 5.74%, which is consistent with historical cardiovascular outcome studies, including those published since the design of REDUCE-IT, with comparable patient populations and expanded or hard major adverse cardiovascular events (MACE) (4,8,9,30-44).”
From Effects of Icosapent Ethyl on Total Ischemic Events (2019) · cites this paper as [31]
In the citing paper
“Excepting glimepiride, which was assessed for CV safety and efficacy head-to-head against linagliptin in the CAROLINA trial, and gliclazidemodified release, which was compared with usual care (that could have included treatment with a sulphonylurea other than gliclazide) in the ADVANCE trial, dedicated CV safety assessments have not been conducted for the other sulphonylureas.132,173,174,184”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [174]
In the citing paper
“Sitagliptin and linagliptin had a neutral effect.174,[178][179][180]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [174]
In the citing paper
“In 4 trials to date, the DPP4 inhibitors have been shown to be neutral in terms of cardiovascular outcomes.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [215]
In the citing paper
“Not all DPP4 inhibitors are associated with higher rates of HF (Table 8).16 -24,184-186”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [18]
In the citing paper
“Likewise, sitagliptin in the TECOS trial had no signal of excess rates of HF. 18,185”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [18]
In the citing paper
“In mice, GLP-1 causes vasodilation through both GLP-1 receptor-dependent and -independent mechanisms.211”
From The Vasculature in Prediabetes (2018) · cites this paper as [211]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citation10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Self-citationEffect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Self-citationAlogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Robins, J. M., & Finkelstein, D. M. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00779.x · Cited by 877
Zannad, F., Cannon, C. P., Cushman, W. C., Bakris, G. L., Menon, V., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62225-x · Cited by 757
The role of gut hormones in glucose homeostasis
Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30076 · Cited by 628
Pancreatic safety of incretin-based drugs–FDA and EMA assessment
Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1314078 · Cited by 498
Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
(2014) · New England Journal of Medicine · doi:10.1056/nejmx140026 · Cited by 372
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,006
Hariyanto, T. I., & Kurniawan, A. (2021) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-021-00777-4 · Cited by 47
JCS 2023 Guideline on the Primary Prevention of Coronary Artery Disease
Fujiyoshi, A., Kohsaka, S., Hata, J., Hara, M., Kai, H., Masuda, D., Miyamatsu, N., Nishio, Y., Ogura, M., Sata, M., et al. (2024) · Circulation Journal · doi:10.1253/circj.cj-23-0285 · Cited by 55
Li, J., Zheng, J., Wang, S., Lau, H., Fathi, A., & Wang, Q. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00015 · Cited by 48
Dei, A., Spigoni, V., Cito, M., Aldigeri, R., Ridolfi, V., Marchesi, E., Marina, M., Derlindati, E., Aloe, R., Bonadonna, R. C., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0503-0 · Cited by 48
Challenges in the Design and Interpretation of Noninferiority Trials
Macaya, F., Ryan, N., Salinas, P., & Pocock, S. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.06.039 · Cited by 47
Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus
Moon, M. K., Hur, K. Y., Ko, S., Park, S.-O., Lee, B., Kim, J. H., Rhee, S. Y., Kim, H. J., Choi, K. M., & Kim, N. H. (2017) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2017.41.5.357 · Cited by 49
Treatment of type 2 diabetes mellitus in elderly patients
Gómez‐Huelgas, R., Peralta, F. G., Rodríguez‐Mañas, L., Formiga, F., Puig‐Domingo, M., Bravo, J. J. M., Miranda, C., & Ena, J. (2018) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2017.12.004 · Cited by 48
Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes
Wang, X., Zheng, P., Huang, G., Yang, L., & Zhou, Z. (2018) · Clinical and Experimental Medicine · doi:10.1007/s10238-018-0519-0 · Cited by 48
Phrommintikul, A., Wongcharoen, W., Kumfu, S., Jaiwongkam, T., Gunaparn, S., Chattipakorn, S. C., & Chattipakorn, N. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13903 · Cited by 48
The future of new drugs for diabetes management
Bailey, C. J., & Day, C. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107785 · Cited by 48
Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis
Wiciński, M., Górski, K. M., Wódkiewicz, E., Walczak, M., Nowaczewska, M., & Malinowski, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072275 · Cited by 48
Lee, S., Zhou, J., Leung, K. S. K., Wai, A. K. C., Jeevaratnam, K., King, E., Liu, T., Wong, W. T., Chang, C., Wong, I. C. K., et al. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07319-x · Cited by 50
Chadha, M. D., Das, A. K., Deb, P., Gangopadhyay, K. K., Joshi, S., Kesavadev, J., KOVIL, R. R., Kumar, S., Misra, A., & Mohan, V. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01219-x · Cited by 47
DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
Razavi, M. A., Wei, Y., Rao, X., & Zhong, J. (2022) · Military Medical Research · doi:10.1186/s40779-022-00410-2 · Cited by 50
Schnell, O., Standl, E., Catrinoiu, D., Itzhak, B., Lalic, N. M., Rahelić, D., Škrha, J., Valensi, P. E., & Ceriello, A. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0822-4 · Cited by 47
Self-citationWhich treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?
Mazzotti, A., Caletti, M. T., Marchignoli, F., Forlani, G., & Marchesini, G. (2017) · Digestive and Liver Disease · doi:10.1016/j.dld.2016.12.028 · Cited by 46
Stoian, A. P., Sachinidis, A. G., Stoica, R. A., Nikolić, D., Patti, A. M., & Rizvi, A. A. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154295 · Cited by 46
Aoyama, M., Kawase, H., Bando, Y., Monji, A., & Murohara, T. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002081 · Cited by 46
Majumdar, S. R., Josse, R. G., Mu, L., & Eurich, D. T. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-4180 · Cited by 46
Self-citationEkström, N., Svensson, A., Miftaraj, M., Franzén, S., Zethelius, B., Eliasson, B., & Guðbjörnsdóttir, S. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12704 · Cited by 47
Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence
Kawanami, D., Matoba, K., Sango, K., & Utsunomiya, K. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17081223 · Cited by 46
Hung, Y., Lin, C., Chen, H.-J., Chang, M. P., Huang, K. C., Chen, Y.-J., & Chen, C.-C. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4021-4 · Cited by 48
The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD)
Prat, L. I., & Tsochatzis, E. A. (2018) · HORMONES · doi:10.1007/s42000-018-0021-9 · Cited by 46
Sharma, A., Ambrosy, A. P., DeVore, A. D., Margulies, K. B., McNulty, S. E., Mentz, R. J., Hernandez, A. F., Felker, G. M., Cooper, L. B., Lala, A., et al. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12334 · Cited by 46
Mannucci, E., Nreu, B., Montereggi, C., Ragghianti, B., Gallo, M., Giaccari, A., Monami, M., Mannucci, E., Candido, R., Pintaudi, B., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.06.002 · Cited by 47
Tanabe, M., Motonaga, R., Terawaki, Y., Nomiyama, T., & Yanase, T. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12567 · Cited by 45
CD26 and Asthma: a Comprehensive Review
Nieto‐Fontarigo, J. J., González‐Barcala, F. J., José, E. S., Arias, P., Nogueira, M., & Salgado, F. J. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-016-8578-z · Cited by 49
Monami, M., Zannoni, S., Pala, L., Silverii, G. A., Andreozzi, F., Sesti, G., & Mannucci, E. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.03.163 · Cited by 47
Pantalone, K. M., Misra‐Hebert, A. D., Hobbs, T. M., Wells, B. J., Kong, S. X., Chagin, K. M., Dey, T., Milinovich, A., Weng, W., Bauman, J. M., et al. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12613 · Cited by 46
Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations
Blonde, L., Dipp, S., & Cadena, D. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0694-0 · Cited by 49
Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes
Kramer, C. K., Ye, C., Campbell, S., & Retnakaran, R. R. (2018) · JACC Heart Failure · doi:10.1016/j.jchf.2018.05.021 · Cited by 46
Cosentino, F., Ceriello, A., Baeres, F. M. M., Fioretto, P., Garber, A. J., Stough, W. G., George, J. T., Grant, P. J., Khunti, K., Langkilde, A. M., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy677 · Cited by 46
Self-citationLim, S. K., Oh, T. J., Dawson, J., & Sattar, N. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13850 · Cited by 48
Seidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata‐Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.05.004 · Cited by 46
Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
Flores, E., Santos‐Gallego, C. G., Mejia, N. M. D., & Badimón, J. J. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6786-x · Cited by 44
Nesti, L., Pugliese, N. R., Sciuto, P., Tricò, D., Dardano, A., Baldi, S., Pinnola, S., Fabiani, I., Bello, V. D., & Natali, A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01618-1 · Cited by 44
Incretin-Based Therapy for Prevention of Diabetic Vascular Complications
Mima, A. (2015) · Journal of Diabetes Research · doi:10.1155/2016/1379274 · Cited by 46
An overview of new GLP-1 receptor agonists for type 2 diabetes
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1123249 · Cited by 49
Manrique, C. M., Habibi, J., Aroor, A. R., Sowers, J. R., Jia, G., Hayden, M. R., Garro, M., Martinez‐Lemus, L. A., Ramirez‐Perez, F. I., Klein, T., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0414-5 · Cited by 44
Dey, J. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1307081 · Cited by 44
Kim, Y., Yoon, D., Park, S.-Y., Han, S. J., Kim, D. J., Lee, K. W., Park, R. W., & Kim, H. J. (2017) · Circulation Heart Failure · doi:10.1161/circheartfailure.117.003957 · Cited by 45
Okabe, K., Matsushima, S., Ikeda, S., Ikeda, M., Ishikita, A., Tadokoro, T., Enzan, N., Yamamoto, T., Sada, M., Deguchi, H., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.14400 · Cited by 44
Giugliano, D., Bellastella, G., Longo, M., Scappaticcio, L., Maiorino, M. I., Chiodini, P., & Esposito, K. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14047 · Cited by 44
Valente, T., & Arbex, A. K. (2020) · Current Diabetes Reviews · doi:10.2174/1573399816666200716201550 · Cited by 44
Sinclair, A. J., Pennells, D., & Abdelhafiz, A. H. (2022) · Aging Clinical and Experimental Research · doi:10.1007/s40520-022-02142-8 · Cited by 45
Liakos, C. I., Papadopoulos, D. P., Sanidas, E. A., Markou, M. I., Hatziagelaki, E. E., Grassos, C. A., Velliou, M. L., & Barbetseas, J. D. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00423-z · Cited by 43
Diabetes and coronary artery disease: not just a risk factor
Grant, P. J., Cosentino, F., & Marx, N. (2020) · Heart · doi:10.1136/heartjnl-2019-316243 · Cited by 45
Zhou, Y., Suo, W., Zhang, X., Liang, J., Zhao, W., Wang, Y., Li, H., & Ni, Q. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115669 · Cited by 43
Effect of Linagliptin on Vascular Function: A Randomized, Placebo-controlled Study
Baltzis, D., Dushay, J. R., Loader, J., Wu, J. S., Greenman, R. L., Roustit, M., & Veves, A. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2655 · Cited by 44
Darsalia, V., Klein, T., Nyström, T., & Patrone, C. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.08.022 · Cited by 43
What have we learnt from “real world” data, observational studies and meta‐analyses
Chatterjee, S., Davies, M. J., & Khunti, K. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13178 · Cited by 43
Weidner, K., Behnes, M., Schupp, T., Rusnak, J., Reiser, L., Bollow, A., Taton, G., Reichelt, T., Ellguth, D., Engelke, N., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0768-y · Cited by 43
Peralta, F. G., Escalada, J., Torre, E. L. M., Mata‐Cases, M., García, J. C. F., Loiola, P. E., Lachica, L. Á., Pérez, J. A. F., Menéndez, S. A., Guisasola, F. Á., et al. (2018) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2018.08.004 · Cited by 46
Carbone, S., Dixon, D. L., Buckley, L. F., & Abbate, A. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.07.018 · Cited by 44
National Trends in Diabetes Medication Use in the United States: 2008 to 2015
Raval, A. D., & Vyas, A. (2018) · Journal of Pharmacy Practice · doi:10.1177/0897190018815048 · Cited by 45
Choi, B., Kim, E., Kim, J.-E., Oh, S., Park, S.-O., Kim, S.-M., Choi, H., Song, J., & Chang, E. (2021) · Cells · doi:10.3390/cells10010057 · Cited by 43
Savarese, G., Butler, J., Lund, L. H., Bhatt, D. L., & Anker, S. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab271 · Cited by 45
Griffin, S. J. (2022) · Diabetologia · doi:10.1007/s00125-022-05782-7 · Cited by 46
Wang, A., Tang, H., Zhang, N., & Feng, X. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109080 · Cited by 44
Role of Gut Microbial Metabolites in Cardiovascular Diseases—Current Insights and the Road Ahead
Datta, S., Pasham, S., Sandeep, I. S., Boini, K. M., & Koka, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810208 · Cited by 42
Shigiyama, F., Kumashiro, N., Miyagi, M., Iga, R., Kobayashi, Y., Kanda, E., Uchino, H., & Hirose, T. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12587 · Cited by 43
Albrechtsen, N. J. W., Albrechtsen, R., Bremholm, L., Svendsen, B., Kuhre, R. E., Poulsen, S. S., Christiansen, C. B., Jensen, E. P., Janus, C., Hilsted, L., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.11.051 · Cited by 42
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure
Kosiborod, M., Gause‐Nilsson, I. A. M., Xu, J. L., Sonesson, C., & JOHNSSON, E. K. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.02.001 · Cited by 43
Lei, Y., Hu, L., Yang, G., Piao, L., Jin, M., & Cheng, X. W. (2017) · Circulation Journal · doi:10.1253/circj.cj-16-1326 · Cited by 42
Cardiovascular disease prevention strategies for type 2 diabetes mellitus
Katsiki, N., Purrello, F., Tsioufis, C. P., & Mikhailidis, D. P. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1351946 · Cited by 42
Lim, S. K., Eckel, R. H., & Koh, K. K. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.03.013 · Cited by 45
FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later
McGuire, D. K., Marx, N., Johansen, O. E., Inzucchi, S. E., Rosenstock, J., & George, J. T. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13645 · Cited by 44
Self-citationHe, L., Wang, J., Ping, F., Yang, N., Huang, J., Li, W., Xu, L., Zhang, H., & Li, Y. (2022) · BMJ · doi:10.1136/bmj-2021-068882 · Cited by 43
Hupfeld, C., & Mudaliar, S. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13740 · Cited by 41
Potentials of incretin‐based therapies in dementia and stroke in type 2 diabetes mellitus
Groeneveld, O. N., Kappelle, L. J., & Biessels, G. J. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12420 · Cited by 42
Son, J. W., & Kim, S. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.5.373 · Cited by 41
Zhu, X., Gillespie, D. G., & Jackson, E. K. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00070.2015 · Cited by 41
The metabolic vascular syndrome - guide to an individualized treatment
Hanefeld, M., Pistrosch, F., Bornstein, S. R., & Birkenfeld, A. L. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9345-4 · Cited by 44
Tanaka, A., Inoue, T., Kitakaze, M., Oyama, J.-I., Sata, M., Taguchi, I., Shimizu, W., Watada, H., Tomiyama, H., Ako, J., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0381-x · Cited by 41
Elgendy, I. Y., Mahmoud, A. N., Barakat, A. F., Elgendy, A. Y., Saad, M. S., Abu‐Zaid, A., Wayangankar, S. A., & Bavry, A. A. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0208-x · Cited by 41
Wang, M.-T., Lin, S., Tang, P., Hung, W.-T., Cheng, C.-C., Yang, J.-S., Chang, H., Liu, C., Mar, G.-Y., & Huang, W. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0572-0 · Cited by 41
Novel therapies for diabetic kidney disease
Cherney, D. Z. I., & Bakris, G. L. (2017) · Kidney International Supplements · doi:10.1016/j.kisu.2017.10.005 · Cited by 41
Management Strategies for Posttransplant Diabetes Mellitus after Heart Transplantation: A Review
Cehic, M. G., Nundlall, N., Greenfield, J. R., & Macdonald, P. S. (2018) · Journal of Transplantation · doi:10.1155/2018/1025893 · Cited by 41
Tratamiento de la diabetes mellitus tipo 2 en el paciente anciano
Gómez‐Huelgas, R., Peralta, F. G., Rodríguez‐Mañas, L., Formiga, F., Puig‐Domingo, M., Bravo, J. J. M., Miranda, C., & Ena, J. (2018) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2017.12.003 · Cited by 42
Adapting Medication for Type 2 Diabetes to a Low Carbohydrate Diet
Cucuzzella, M. T., Riley, K., & Isaacs, D. M. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.688540 · Cited by 42
Tanaka, M., Matsuo, Y., Yamakage, H., Masuda, S., Terada, Y., Muranaka, K., Wada, H., Hasegawa, K., Shimatsu, A., & Satoh‐Asahara, N. (2015) · Metabolism · doi:10.1016/j.metabol.2015.10.009 · Cited by 41
Treatment of dyslipidemia in diabetes: recent advances and remaining questions
Chait, A., & Goldberg, I. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0942-8 · Cited by 40
Sagara, M., Suzuki, K., Aoki, C., Tanaka, S., Taguchi, I., Inoue, T., & Aso, Y. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0396-3 · Cited by 40
Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis
Waldrop, G. E., Zhong, J., Peters, M. C., Goud, A., Chen, Y., Davis, S. N., Mukherjee, B., & Rajagopalan, S. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.08.018 · Cited by 40
Emerging roles of sodium–glucose cotransporter 2 inhibitors in cardiology
Tanaka, A., & Node, K. (2016) · Journal of Cardiology · doi:10.1016/j.jjcc.2016.10.019 · Cited by 40
The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors
Secrest, M. H., Udell, J. A., & Filion, K. B. (2017) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2017.01.009 · Cited by 41
Cardiac Effects of Sulfonylurea-Related Hypoglycemia
Middleton, T. L., Wong, J., Molyneaux, L. M., Brooks, B. A., Yue, D. K., Twigg, S. M., & Wu, T. (2017) · Diabetes Care · doi:10.2337/dc16-1972 · Cited by 40
Leiter, L. A., Shestakova, M. V., & Satman, İ. (2018) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-018-0331-8 · Cited by 41
Giugliano, D., Chiodini, P., Maiorino, M. I., Bellastella, G., & Esposito, K. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01047-0 · Cited by 41
Xiang, G., Huang, X., Wang, T., Wang, J., Zhao, G., Wang, H., Feng, Y., Lei, W., & Hu, X. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110078 · Cited by 40
Zhou, Y., Zhang, Y., Zhang, R., Zhou, Y., Li, N., Wang, M., Tian, H., & Li, S. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001407 · Cited by 39
Cellular mechanisms and recommended drug-based therapeutic options in diabetic cardiomyopathy
Dannenberg, L., Weske, S., Kelm, M., Levkau, B., & Polzin, A. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107920 · Cited by 40
Role of diabetes in stroke: Recent advances in pathophysiology and clinical management
Bradley, S., Spring, K. J., Beran, R. G., Chatzis, D., Killingsworth, M. C., & Bhaskar, S. M. M. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3495 · Cited by 42
Piepoli, M. F., Adamo, M., Barison, A., Bestetti, R. B., Biegus, J., Böhm, M., Butler, J., Carapetis, J. R., Ceconi, C., Chioncel, O. D., et al. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab147 · Cited by 43
The Role of Dipeptidyl Peptidase – 4 Inhibitors in Diabetic Kidney Disease
Panchapakesan, U., & Pollock, C. A. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00443 · Cited by 39
Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm
Wilding, J. P. H., Rajeev, S. P., & DeFronzo, R. A. (2016) · Diabetes Care · doi:10.2337/dcs15-3005 · Cited by 40
Scheen, A. J. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0498-9 · Cited by 39
Cardioprotective anti-hyperglycaemic medications: a review of clinical trials
Ahmed, H. M., Khraishah, H., & Cho, L. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx668 · Cited by 40
Lamos, E. M., Hedrington, M. S., & Davis, S. N. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1626823 · Cited by 39
DPP-4 Inhibitor–Related Pancreatitis: Rare but Real!
DeVries, J. H., & Rosenstock, J. (2017) · Diabetes Care · doi:10.2337/dci16-0035 · Cited by 40
Metadata
- Authors
- Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., Lachin, J. M., McGuire, D. K., Pencina, M. J., Standl, E., Stein, P. P., Suryawanshi, S., Van de Werf, F., Peterson, E. D., & Holman, R. R.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- University of Oxford (GB)
- University of Alberta (CA)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Duke University (US)
- St. Michael's Hospital (CA)
- George Washington University (US)
- The University of Texas Southwestern Medical Center (US)
- Helmholtz Munich (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-07-16
- Volume
- 373
- Issue
- 3
- Pages
- 232-242
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2142830692
- Semantic Scholar
- 5f5aabad35a6c6137b19d8640d5d6cafc91815e5
- Cited by
- 2,577
- References
- 16
- Citations by year
- 2026: 68 · 2025: 121 · 2024: 120 · 2023: 139 · 2022: 170 · 2021: 210 · 2020: 289 · 2019: 267 · 2018: 343 · 2017: 343 · 2016: 378 · 2015: 120
- FWCI
- 341.75
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (acceptedVersion, cc-by-nc-nd)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lithuanian University of Health Sciences (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- UNC Libraries
- Funders
- South Australian Health and Medical Research Institute
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- sitagliptin, type 2 diabetes, cardiovascular disease, DPP-4 inhibitors, major adverse cardiovascular events, heart failure hospitalization, acute pancreatitis, pancreatic cancer, HbA1c, glycemic control, non-inferiority
- MeSH terms
- Sitagliptin Phosphate, Administration, Oral, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Follow-Up Studies, Heart Diseases, Heart Failure, Glycated Hemoglobin, Hospitalization, Humans, Hypoglycemic Agents, Pyrazines, Triazoles, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
